United States v. Benjamin Galecki

932 F.3d 176
CourtCourt of Appeals for the Fourth Circuit
DecidedJuly 29, 2019
Docket18-4727; 18-4730
StatusPublished
Cited by14 cases

This text of 932 F.3d 176 (United States v. Benjamin Galecki) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Benjamin Galecki, 932 F.3d 176 (4th Cir. 2019).

Opinion

AGEE, Circuit Judge:

*180 A federal jury convicted Benjamin Galecki and Charles Burton Ritchie ("Defendants") of charges related to a conspiracy to distribute controlled substance analogues. Defendants then appealed to this Court for the first time, challenging several of the trial court's rulings, including the failure to compel a Drug Enforcement Administration (DEA) chemist to testify on their behalf, the exclusion of certain evidence, and the formulation of a jury instruction. In that appeal, we upheld the jury instruction, but vacated Defendants' convictions and remanded the case for the district court to determine whether the DEA chemist's testimony was material to their case. United States v. Ritchie , 734 F. App'x 876 (4th Cir. 2018) ( Ritchie II ). On remand, the district court held the chemist's testimony was not material and declined to compel his presence at trial. United States v. Ritchie , No. 4:15-cr-18, 2018 WL 4693811 (E.D. Va. Sept. 28, 2018) ( Ritchie III ). Defendants now appeal that decision and renew several other evidentiary challenges that we declined to address in the prior appeal. As discussed below, we affirm in part, reverse in part, vacate Defendants' convictions, and remand for a new trial.

I.

A.

Federal law prohibits the distribution of a controlled substance analogue. See 21 U.S.C. §§ 813 , 841(a)(1). The Analogue Act defines "controlled substance analogue" as a substance-

(i) the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II;
(ii) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or
(iii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II.

21 U.S.C. § 802 (32)(A). Because an Analogue Act conviction requires proof of a defendant's knowledge and intent, that is, his mens rea, the Government must show that he knew either that the substance at issue is a controlled substance or that it is "substantially similar" to a controlled substance in both chemical structure and physiological effects. See id. This Court has explained that a person has violated the Analogue Act if he

(1) distributed a substance that had the chemical structure of an analogue and the actual, intended, or claimed physiological effects of an analogue; (2) intended that the substance be used for human consumption; and (3) knew either the legal status of the substance, or the chemical structure and physiological effects of that substance.

United States v. McFadden , 823 F.3d 217 , 223 (4th Cir. 2016).

*181 B.

From 2010 to 2013, Defendants operated Zencense Incenseworks, LLC, which had facilities in Pensacola, Florida, and Las Vegas, Nevada. Zencense manufactured and sold a substance commonly called "spice," which contained a mix of crushed leaves and chemical additives. Consumers would generally smoke the spice, but Defendants packaged the product as "incense" and labeled it "Not for human consumption." J.A. 633. In late March or early April 2012, Defendants began using the chemical additives XLR-11 and UR-144 in their manufactured spice. These additives were not on the controlled substances drug schedule during the time period of the alleged conspiracy (February 8, 2012 to April 30, 2013). 1 Defendants shipped their product around the country for sale by various retailers, including one in Hampton Roads, Virginia, which received a shipment on August 9, 2012. 2

The Government had begun investigating Zencense's operations because it suspected Defendants' "incense" was actually synthetic marijuana, i.e., a substance "designed and intended to have an effect similar to controlled substances" (marijuana) when smoked. J.A. 110. In the Government's view, this physiological effect, coupled with the chemical similarity of the additive XLR-11 to the controlled chemical in marijuana, JWH-018, makes Defendants' spice a controlled substance analogue within the meaning of 21 U.S.C. § 802 (32)(A). On that basis, the Government charged Defendants with conspiring to distribute controlled substances and controlled substance analogues, in violation of 21 U.S.C. §§ 846 , 813 ; using a communication facility to promote unlawful activity, in violation of 21 U.S.C. § 843 (b) and 18 U.S.C. § 2 ; using a facility in interstate commerce to promote unlawful activity, in violation of 18 U.S.C. §§ 1952 (a)(3), 2; and distributing controlled substances and controlled substance analogues, in violation of

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Cristian Cabrera-Rivas
142 F.4th 199 (Fourth Circuit, 2025)
United States v. David Chang
Fourth Circuit, 2024
United States v. Eicher
District of Columbia, 2023
WALLS v. FORD MOTOR COMPANY
M.D. North Carolina, 2022
United States v. Velazquez-Fontanez
6 F. 4th 205 (First Circuit, 2021)
LEE v. United States
D. New Jersey, 2021
United States v. Requena
980 F.3d 30 (Second Circuit, 2020)
Settle v. Stepp
S.D. West Virginia, 2020

Cite This Page — Counsel Stack

Bluebook (online)
932 F.3d 176, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-benjamin-galecki-ca4-2019.